Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease – a systematic review

Globally, 25% of people have Non-Alcoholic Fatty Liver Disease (NAFLD) and currently there are no approved pharmacological treatments for NAFLD. With a slow disease progression, long-term impact of pharmacological treatments can only be assessed by complementing emerging clinical trial evidence by data from other sources in disease progression modelling. Although this modelling is crucial for economic evaluation studies assessing the clinical and economic consequences of new treatments the approach to modelling the natural history of NAFLD differs in contemporary research.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research